NanoArrayer™ a Key Element in Harvard Research Project
News Apr 20, 2006
BioForce Nanosciences has received a letter of intent to purchase a NanoArrayer™ System from the Technology & Engineering Center at the Harvard Medical School (HMS).
Funding for the purchase will come from a National Human Genome Research Institute (NHGRI) award with purchase and installation of the technology expected later this summer.
Dale Larson, principal investigator on this project, is the Director of the Technology and Engineering Center (TEC) at HMS.
In the letter of intent Larson noted, "Our nanohole array sensors can be made as small as 0.050 micron x 1.050 micron and as far as I know your technology is the only commercially available method to print such small areas."
"In the genomics and proteomics fields as samples continue to shrink in size and sample numbers continue to increase, these smaller sensor platforms become critical."
Michael Lynch, Product Manager for the NanoArrayer™ System coordinated closely with Larson in the grant submission process for obtaining funding for the instrument.
"We are very excited about this placement. Using the NanoArrayer System to activate or functionalize these very small biosensors is a key application for this technology."
"As sensor detection platforms reduce in size, it becomes a challenge to print a variety of detector molecules on such a small surface area. The NanoArrayer™ System is designed to meet this market need."
Dr. Eric Henderson, Founder and CEO of BioForce Nanosciences, commented, "We are pleased to see firm plans for the sale of a NanoArrayer™System to this prestigious institution."
"The groundbreaking work performed at Harvard will provide validation of the value that this enabling technology provides to biosensor technology development. We look forward to working with Dale and his group."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.